Your browser doesn't support javascript.
loading
Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients.
Zaragoza-Huesca, David; Nieto-Olivares, Andrés; García-Molina, Francisco; Ricote, Guillermo; Montenegro, Sofía; Sánchez-Cánovas, Manuel; Garrido-Rodríguez, Pedro; Peñas-Martínez, Julia; Vicente, Vicente; Martínez, Francisco; Lozano, María Luisa; Carmona-Bayonas, Alberto; Martínez-Martínez, Irene.
Afiliação
  • Zaragoza-Huesca D; Centro Regional de Hemodonación, Department of Haematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30100 Murcia, Spain.
  • Nieto-Olivares A; Department of Pathology, Hospital General Universitario Morales Meseguer, 30008 Murcia, Spain.
  • García-Molina F; Department of Pathology, Hospital General Universitario Reina Sofía, 30003 Murcia, Spain.
  • Ricote G; Centro Regional de Hemodonación, Department of Haematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30100 Murcia, Spain.
  • Montenegro S; Centro Regional de Hemodonación, Department of Haematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30100 Murcia, Spain.
  • Sánchez-Cánovas M; Centro Regional de Hemodonación, Department of Haematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30100 Murcia, Spain.
  • Garrido-Rodríguez P; Centro Regional de Hemodonación, Department of Haematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30100 Murcia, Spain.
  • Peñas-Martínez J; Centro de Investigación Biomédica en Red de Enfermedades Raras, U-765-CIBERER, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Vicente V; Centro Regional de Hemodonación, Department of Haematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30100 Murcia, Spain.
  • Martínez F; Centro Regional de Hemodonación, Department of Haematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30100 Murcia, Spain.
  • Lozano ML; Centro de Investigación Biomédica en Red de Enfermedades Raras, U-765-CIBERER, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Carmona-Bayonas A; Department of Pathology, Hospital General Universitario Reina Sofía, 30003 Murcia, Spain.
  • Martínez-Martínez I; Centro Regional de Hemodonación, Department of Haematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30100 Murcia, Spain.
Cancers (Basel) ; 14(13)2022 Jun 24.
Article em En | MEDLINE | ID: mdl-35804878
ABSTRACT
Hepsin is a type II transmembrane serine protease whose deregulation promotes tumor invasion by proteolysis of the pericellular components. In colorectal cancer, the implication of hepsin is unknown. Consequently, we aimed to study the correlations between hepsin expression and different clinical-histopathological variables in 169 patients with localized colorectal cancer and 118 with metastases. Tissue microarrays were produced from samples at diagnosis of primary tumors and stained with an anti-hepsin antibody. Hepsin expression was correlated with clinical-histopathological variables by using the chi-square and Kruskal−Wallis tests, Kaplan−Meier and Aalen−Johansen estimators, and Cox and Fine and Gray multivariate models. In localized cancer patients, high-intensity hepsin staining was associated with reduced 5-year disease-free survival (p-value = 0.16). Medium and high intensity of hepsin expression versus low expression was associated with an increased risk of metastatic relapse (hazard ratio 2.83, p-value = 0.035 and hazard ratio 3.30, p-value = 0.012, respectively), being a better prognostic factor than classic histological variables. Additionally, in patients with localized tumor, 5-year thrombosis cumulative incidence increased with the increment of hepsin expression (p-value = 0.038). Medium and high intensities of hepsin with respect to low intensity were associated with an increase in thrombotic risk (hazard ratio 7.71, p-value = 0.043 and hazard ratio 9.02, p-value = 0.028, respectively). This relationship was independent of previous tumor relapse (p-value = 0.036). Among metastatic patients, low hepsin expression was associated with a low degree of tumor differentiation (p-value < 0.001) and with major metastatic dissemination (p-value = 0.023). Hepsin is a potential thrombotic and metastatic biomarker in patients with localized colorectal cancer. In metastatic patients, hepsin behaves in a paradoxical way with respect to differentiation and invasion processes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha